A molecular model of the F12 biotherapy shows the fold of its polypeptide backbone. Residual T-cell epitopes are mapped onto the structure and colored from white (no epitopes) to dark red (dense overlapping epitopes). The muted red coloring indicates that T-cell epitopes have been broadly silenced in the engineered F12 variant, and this reduced epitope content underlies the molecule’s improved safety and efficacy profile.
The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States. Now, a new study led by Dartmouth engineering researchers shows promise for an engineered lysin-based antibacterial agent that may enable safe, repeated dosing to treat life-threatening infections by MRSA and other types of S. aureus.
In recent years, lysins—enzymes naturally produced by microbes and associated viruses—have shown potential to treat S. aureus, which can rapidly acquire resistance to other types of antibiotic drugs.
“Lysins are one of the most promising next-generation antibiotics. They kill drug-sensitive and drug-resistant bacteria with equal efficacy, they can potentially suppress new resistance phenotypes, and they also have this laser-like precision,” said Dartmouth engineering professor and corresponding author Karl Griswold.
While there is promise in lysins, development has been slowed due to concerns that they prompt humans’ immune systems to develop antidrug antibodies, which can have negative side effects including life-threatening hypersensitivity reactions.
That’s why the Dartmouth engineering team—which also included researchers in Dartmouth’s computer science department, The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon, and Stealth Biologics—engineered and patented F12, a new lysin-based antibacterial agent. F12 is essentially able to hide from the human immune system (due to T cell epitope deletion), and therefore does not cause the same negative side effects as unmodified, natural lysins.
F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections. Preclinical studies showed the efficacy of F12 does not diminish with repeated doses, while two other anti-MRSA lysin treatments currently in clinical trials are only designed to be used a single time.
“We have engineered this super potent, super effective anti-MRSA biotherapeutic, and we’ve done it in a way that renders it compatible with and largely invisible to the human immune system. By making it a safer drug, we’ve enabled the possibility of dosing multiple times in order to treat even the most highly refractory infections,” said Griswold.
The team’s paper, “Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing,” was published earlier today by Science Advances. The work was the result of two grants from the National Institutes of Health (NIH) totaling $1.7 million.
The paper details the treatment’s positive results in rabbits, mice with partially-humanized immune systems, and studies with extracted human immune cells. Griswold believes the antibacterial agent could be ready for human clinical trials as soon as 2023.
“This is the first report of a translation-ready deimmunized lysin, and F12 has serious, bonafide clinical potential,” said Griswold.
Further studies of F12 will examine synergy with standard-of-care antibacterial chemotherapies. Preliminary results suggest the combinations are extremely potent and suppress drug-resistance phenotypes.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug resistant bacteria
- Study underscores new strategies to fight drug-resistant bacteria
Several billion years ago, a genetic arms race began between bacteria and their viral killers. This seemingly eternal struggle continues today, with implications for diseases killing tens of thousands ...
- A mother’s loss launches a global effort to fight antibiotic resistance
Diane Shader Smith's daughter, Mallory Smith, died at age 25 after fighting an antibiotic-resistant lung infection for 12 years. A new book of her daughter's diary entries and a website are aimed at ...
- Raw meat-based diet for pets linked to drug-resistant bacteria, prompting concerns over public health risks
Study reveals that raw meat-based pet diets (RMBDs) often harbor multidrug-resistant bacteria, posing significant health risks to both pets and humans, unlike conventionally processed pet foods.
- Bacteria on the ISS has mutated into something never seen on Earth
Scientists have discovered several strains of bacteria never before seen on Earth aboard the International Space Station.
- Medical school scientist creates therapy to kill hypervirulent bacteria
Researchers are on a mission to kill drug-resistant bacteria, and a new study has identified a therapy that can penetrate the slime that such infections use to protect themselves from ...
Go deeper with Google Headlines on:
Drug resistant bacteria
[google_news title=”” keyword=”drug resistant bacteria” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
F12 lysin-based antibacterial agent
- Postoperative Topical Antimicrobial Use
2008;19(4):181-189. In contrast to the case of closed wounds, the bacterial colonization of open wounds and the efficacy of topical antimicrobial agents in such situations as they relate to ...
- CRISPR is promising to tackle antimicrobial resistance, but remember bacteria can fight back
Cas proteins conduct adaptive immunity in prokaryotes (bacteria) based on immunological memories ... can also be employed for developing antimicrobial agents: introduction of self-targeting ...
- Researchers systematically investigate efficacy of CRISPR antimicrobial agents
The antimicrobial potential of CRISPR-Cas systems is promising, yet how to best design or implement CRISPR nucleases remains poorly understood. An international team led by the Helmholtz Institute for ...
- Antimicrobial agents of the future
HIRI researchers conducted the first systematic study of CRISPR-based antibiotics in Klebsiella pneumonia The antimicrobial potential ... pipeline for new agents has slowed, while the improper ...
- Odor-causing bacteria in armpits targeted using bacteriophage-derived lysin
A research team has synthesized a lysin that during in vitro experiments targets bacteria responsible for producing odors in human armpits.
Go deeper with Google Headlines on:
F12 lysin-based antibacterial agent
[google_news title=”” keyword=”F12 lysin-based antibacterial agent” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]